Detecting idiosyncratic reactions is challenging due to their unpredictable nature. Traditional toxicity testing, which relies on standard animal models, often fails to predict these reactions because the models do not replicate human genetic diversity. As a result, post-marketing surveillance of drugs becomes crucial in identifying such reactions. Healthcare professionals play a critical role by reporting adverse drug reactions to pharmacovigilance systems.
